@article{JTD24508,
author = {Paolo Bironzo and Riccardo Taulli},
title = {NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 33},
year = {2018},
keywords = {},
abstract = {Malignant pleural mesothelioma (MPM), which is linked to asbestos exposure and is a rare, lethal disease of the serosal membrane in the chest, has an incidence which continues to increase worldwide (1,2). MPM is histologically classified into three major subtypes: epithelioid, biphasic (or mixed) and sarcomatoid. Notwithstanding these well-defined MPM histological subtypes, there are tremendous differences in clinical outcomes including long-term survival in patients whose tumor histology is indistinguishable from conventional, highly aggressive MPM.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24508}
}